

## For immediate release

April 16, 2001  
Kyorin Pharmaceuticals  
2-5 Kanda Surugadai, Chiyoda-ku, Tokyo  
TSE 1<sup>st</sup> Section, Stock code: 4560

### Business start of US-based corporation, Kyorin USA, Inc.

Kyorin Pharmaceutical (President Ikuo Ogihara) is announcing the start of business of its base for business development in the United States, Kyorin USA, Inc., a 100% owned entity based in New Jersey (April 16, 2001 local time).

The purpose of Kyorin USA, Inc. is to accelerate our business growth mainly in the US market by licensing Kyorin drugs into the growing US market and by obtaining the license for new other maker's drugs into Japan.

The company will be involved in the evaluation of other company technology, alliances and licensing research and analysis, and negotiations, in addition to conducting US-based trials for our drugs. We will also strengthen our industry information gathering ability through contact with university and R&D facilities that produce seed drugs, and observing R&D trends in pharmaceuticals and new drug development.

Kyorin USA, Inc. started business with a staff of five.

Kyorin USA, Inc.  
300 Frank W. Burr Blvd. 5th Floor, Teaneck, New Jersey 07666  
Ph: + 1 - 2 0 1 - 2 8 7 - 0 1 1 0  
Fax: + 1 - 2 0 1 - 2 8 7 - 0 1 3 9

Start of business: April 16, 2001

President : Kenji Akutsu

Operations: Kyorin USA is involved in the following activities, which are related to Kyorin Pharmaceutical's pharmaceutical business in America

1. Evaluate other company technology, alliance and licensing research, analysis and negotiations
2. Activities involving clinical trials being conducted in the US
3. Gathering and analysing of information on drug R&D, and pharmaceutical and medical government policy
4. Other supportive business conducted by Kyorin

Questions and comments can be directed to:

Planning Office  
Kyorin Pharmaceutical  
Ph: 03-3293-3414  
Fax: 03-3293-3450